{"id":"algeldrate","rwe":[{"pmid":"8767354","year":"1996","title":"Comparison of the effects of ranitidine effervescent tablets and magnesium hydroxide-aluminium oxide on intragastric acidity. A single-centre, randomised, open cross-over study.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"3573126","year":"1986","title":"Intestinal absorption of aluminium from antacids: a comparison between hydrotalcite and algeldrate.","finding":"","journal":"Journal of toxicology. Clinical toxicology","studyType":"Clinical Study"}],"_fda":{"id":"4aba2043-4dde-0c18-e063-6294a90a5fcf","set_id":"2d74e5bc-1f10-4fb6-9258-cd906e360013","openfda":{"unii":["5QB0T2IUN0","0E53J927NA"],"route":["ORAL"],"rxcui":["245001","252203","404472","1251365"],"spl_id":["4aba2043-4dde-0c18-e063-6294a90a5fcf"],"brand_name":["GAVISCON"],"spl_set_id":["2d74e5bc-1f10-4fb6-9258-cd906e360013"],"package_ndc":["0135-0094-41","0135-0094-42","0135-0095-41","0135-0574-01"],"product_ndc":["0135-0094","0135-0095","0135-0574"],"generic_name":["ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ALUMINUM HYDROXIDE","MAGNESIUM CARBONATE"],"manufacturer_name":["Haleon US Holdings LLC"],"application_number":["M001"],"is_original_packager":[true]},"purpose":["Purposes Antacid Antacid"],"version":"23","warnings":["Warnings Ask a doctor or pharmacist before use if you have kidney disease are on a sodium-restricted diet or a magnesium-restricted diet are taking a prescription drug. Antacids may interact with certain prescription drugs. When using this product (Regular Strength) do not take more than 8 tablespoonfuls in 24 hours do not use the maximum dosage for more than 2 weeks except under the advice and supervision of a doctor laxative effect may occur When using this product (Extra Strength) do not take more than 16 teaspoonfuls in 24 hours do not use the maximum dosage for more than 2 weeks, except under the advice and supervision of a doctor laxative effect may occur Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"questions":["Questions or comments? 1-800-452-0051"],"when_using":["When using this product (Regular Strength) do not take more than 8 tablespoonfuls in 24 hours do not use the maximum dosage for more than 2 weeks except under the advice and supervision of a doctor laxative effect may occur","When using this product (Extra Strength) do not take more than 16 teaspoonfuls in 24 hours do not use the maximum dosage for more than 2 weeks, except under the advice and supervision of a doctor laxative effect may occur"],"effective_time":"20260213","active_ingredient":["Active ingredients (in each 15 mL tablespoonful) Regular Strength Aluminum hydroxide 95 mg Magnesium carbonate 358 mg","Active ingredients (in each 5 mL / teaspoonful) Extra Strength Aluminum hydroxide 254 mg Magnesium carbonate 237.5 mg"],"inactive_ingredient":["Inactive ingredients (Regular Strength) benzyl alcohol, D&C yellow #10, edetate disodium, FD&C blue #1, flavor, glycerin, saccharin sodium, sodium alginate, sorbitol solution, water, xanthan gum","Inactive ingredients (Extra Strength Cool Mint) benzyl alcohol, edetate disodium, glycerin, natural and artificial flavors, purified water, simethicone emulsion, sodium alginate, sodium saccharin, sorbitol solution, xanthan gum","Inactive ingredients (Extra Strength Cherry) benzyl alcohol, edetate disodium, glycerin, natural and artificial flavors, purified water, simethicone emulsion, sodium alginate, sodium saccharin, sorbitol solution, xanthan gum"],"storage_and_handling":["Other information (Regular Strength) each tablespoon (15 mL) contains: magnesium 115 mg, sodium 52 mg store at up to 25°C (77°F). Avoid freezing. keep tightly closed","Other information (Extra Strength) each teaspoon (5 mL) contains: magnesium 75 mg, sodium 11 mg store at up to 25°C (77°F). Avoid freezing. keep tightly closed"],"indications_and_usage":["Uses relieves heartburn acid indigestion sour stomach upset stomach associated with these symptoms"],"ask_doctor_or_pharmacist":["Ask a doctor or pharmacist before use if you have kidney disease are on a sodium-restricted diet or a magnesium-restricted diet are taking a prescription drug. Antacids may interact with certain prescription drugs."],"spl_unclassified_section":["Additional Information Do not use if printed inner safety seal under cap is broken or missing. Trademarks are owned by or licensed to the Haleon group of companies. ©2025 Haleon group of companies or its licensor. Pat. Info www.productpats.com Distributed by: Haleon Warren, NJ 07059 Made in Mexico"],"dosage_and_administration":["Directions (Regular Strength) shake well take 1-2 tablespoonfuls four times a day or as directed by a doctor take after meals and at bedtime dispense product only by spoon or other measuring device","Directions (Extra Strength) shake well take 2-4 teaspoonfuls four times a day or as directed by a doctor take after meals and at bedtime dispense product only by spoon or other measuring device"],"spl_product_data_elements":["GAVISCON aluminum hydroxide and magnesium carbonate BENZYL ALCOHOL EDETATE DISODIUM GLYCERIN WATER SODIUM ALGINATE SACCHARIN SODIUM SORBITOL XANTHAN GUM ALUMINUM HYDROXIDE ALUMINUM HYDROXIDE MAGNESIUM CARBONATE CARBONATE ION cool mint GAVISCON aluminum hydroxide and magnesium carbonate BENZYL ALCOHOL DIMETHICONE, UNSPECIFIED EDETATE DISODIUM GLYCERIN SACCHARIN SODIUM SODIUM ALGINATE SORBITOL XANTHAN GUM WATER ALUMINUM HYDROXIDE ALUMINUM HYDROXIDE MAGNESIUM CARBONATE CARBONATE ION cool mint GAVISCON aluminum hydroxide and magnesium carbonate BENZYL ALCOHOL DIMETHICONE, UNSPECIFIED EDETATE DISODIUM GLYCERIN SACCHARIN SODIUM SODIUM ALGINATE SORBITOL WATER XANTHAN GUM ALUMINUM HYDROXIDE ALUMINUM HYDROXIDE MAGNESIUM CARBONATE CARBONATE ION"],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["Principal Display Panel NDC 0135-0094-41 Gaviscon LIQUID ANTACID REGULAR STRENGTH Fast-Acting Heartburn Relief Helps Keep Acid Down for Hours COOL MINT FLAVOR 12 FL OZ (355 mL) FRONT: 00067473 BACK: 00067474 00067473 Gaviscon Regular Strength 12 fl oz","Principal Display Panel HALEON Gaviscon LIQUID ANTACID EXTRA STRENGTH Fast-Acting Heartburn Relief Helps Keep Acid Down for Hours COOL MINT FLAVOR 12 FL OZ (355 mL) FRONT: 00213316 BACK: 00213317 Gaviscon Extra Strength Cool Mint 12 fl oz label.jpg","Principal Display Panel HALEON Gaviscon LIQUID ANTACID EXTRA STRENGTH Fast-Acting Heartburn Relief Helps Keep Acid Down for Hours CHERRY FLAVOR 12 FL OZ (355 mL) FRONT: 00213320 BACK: 00213322 Gaviscon Extra Strength 12 fl oz label.jpg"]},"tags":[{"label":"algeldrate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A02AB01","category":"atc"},{"label":"Topical","category":"route"},{"label":"Oral","category":"route"},{"label":"Cream","category":"form"},{"label":"Gel","category":"form"},{"label":"Granule","category":"form"},{"label":"Liquid","category":"form"},{"label":"Active","category":"status"},{"label":"Duodenal ulcer disease","category":"indication"},{"label":"Gastric Hypersecretory Conditions","category":"indication"},{"label":"Gastric ulcer","category":"indication"},{"label":"Gastroesophageal reflux disease","category":"indication"},{"label":"Heartburn","category":"indication"},{"label":"Indigestion","category":"indication"},{"label":"Sanofi Aventis Us","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Antacids","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":474.937,"date":"","count":103,"signal":"Schizoaffective disorder","source":"DrugCentral FAERS","actionTaken":"Reported 103 times (LLR=475)"},{"llr":255.494,"date":"","count":105,"signal":"Drug level increased","source":"DrugCentral FAERS","actionTaken":"Reported 105 times (LLR=255)"},{"llr":195.674,"date":"","count":113,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=196)"},{"llr":110.345,"date":"","count":156,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 156 times (LLR=110)"},{"llr":44.106,"date":"","count":10,"signal":"Mesothelioma","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=44)"},{"llr":42.691,"date":"","count":35,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=43)"},{"llr":35.761,"date":"","count":38,"signal":"Acute myocardial infarction","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=36)"},{"llr":35.751,"date":"","count":10,"signal":"Sinus rhythm","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=36)"},{"llr":32.533,"date":"","count":56,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=33)"},{"llr":29.002,"date":"","count":8,"signal":"Violence-related symptom","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=29)"},{"llr":28.063,"date":"","count":21,"signal":"Hepatic cytolysis","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=28)"},{"llr":26.78,"date":"","count":35,"signal":"Delirium","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=27)"},{"llr":26.201,"date":"","count":13,"signal":"Appendicolith","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=26)"},{"llr":25.911,"date":"","count":14,"signal":"Blood phosphorus increased","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=26)"},{"llr":25.219,"date":"","count":127,"signal":"Vomiting","source":"DrugCentral FAERS","actionTaken":"Reported 127 times (LLR=25)"}],"drugInteractions":[{"url":"/drug/cefdinir","drug":"cefdinir","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Cefdinir","source":"DrugCentral","drugSlug":"cefdinir"},{"url":"/drug/cefpodoxime-proxetil","drug":"cefpodoxime proxetil","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Cefpodoxime Proxetil","source":"DrugCentral","drugSlug":"cefpodoxime-proxetil"},{"url":"/drug/ciprofloxacin","drug":"ciprofloxacin","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Ciprofloxacin","source":"DrugCentral","drugSlug":"ciprofloxacin"},{"url":"/drug/doxycycline","drug":"doxycycline","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Doxycycline","source":"DrugCentral","drugSlug":"doxycycline"},{"url":"/drug/eltrombopag","drug":"eltrombopag","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Eltrombopag","source":"DrugCentral","drugSlug":"eltrombopag"},{"url":"/drug/enoxacin","drug":"enoxacin","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Enoxacin","source":"DrugCentral","drugSlug":"enoxacin"},{"url":"/drug/ethambutol","drug":"ethambutol","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Ethambutol","source":"DrugCentral","drugSlug":"ethambutol"},{"url":"/drug/gatifloxacin","drug":"gatifloxacin","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Gatifloxacin","source":"DrugCentral","drugSlug":"gatifloxacin"},{"url":"/drug/itraconazole","drug":"itraconazole","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Itraconazole","source":"DrugCentral","drugSlug":"itraconazole"},{"url":"/drug/ketoconazole","drug":"ketoconazole","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Ketoconazole","source":"DrugCentral","drugSlug":"ketoconazole"},{"url":"/drug/levothyroxine-sodium","drug":"levothyroxine sodium","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Levothyroxine Sodium","source":"DrugCentral","drugSlug":"levothyroxine-sodium"},{"url":"/drug/lomefloxacin","drug":"lomefloxacin","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Lomefloxacin","source":"DrugCentral","drugSlug":"lomefloxacin"},{"url":"/drug/minocycline","drug":"minocycline","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Minocycline","source":"DrugCentral","drugSlug":"minocycline"},{"url":"/drug/moxifloxacin","drug":"moxifloxacin","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Moxifloxacin","source":"DrugCentral","drugSlug":"moxifloxacin"},{"url":"/drug/tetracycline","drug":"tetracycline","action":"Monitor closely","effect":"May interact with Aluminum Hydroxide, Tetracycline","source":"DrugCentral","drugSlug":"tetracycline"},{"url":"/drug/zalcitabine","drug":"zalcitabine","action":"Monitor closely","effect":"ALUMINUM HYDROXIDE/ZALCITABINE (DIDEOXYCYTIDINE,ddC)","source":"DrugCentral","drugSlug":"zalcitabine"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Sanofi","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALGELDRATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:42:14.310545+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Algeldrate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:42:21.354037+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:42:19.884220+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALGELDRATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:42:20.220981+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:42:13.054984+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:42:13.055006+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3833310/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:42:20.998596+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M001","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:42:13.055009+00:00"}},"allNames":"gaviscon","offLabel":[],"synonyms":["aluminum hydroxide","algeldrate","aluminum hydroxide hydrate","aluminium hydroxide"],"timeline":[{"date":"1983-12-09","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"}],"brandName":"Gaviscon","ecosystem":[{"indication":"Duodenal ulcer disease","otherDrugs":[{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"},{"name":"nizatidine","slug":"nizatidine","company":""}],"globalPrevalence":null},{"indication":"Gastric Hypersecretory Conditions","otherDrugs":[{"name":"almasilate","slug":"almasilate","company":""},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"},{"name":"magnesium carbonate","slug":"magnesium-carbonate","company":"United Guardian"},{"name":"magnesium hydroxide","slug":"magnesium-hydroxide","company":"Mcneil Cons"}],"globalPrevalence":null},{"indication":"Gastric ulcer","otherDrugs":[{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"},{"name":"mepenzolate","slug":"mepenzolate","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Gastroesophageal reflux disease","otherDrugs":[{"name":"almasilate","slug":"almasilate","company":""},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"cisapride","slug":"cisapride","company":""},{"name":"dexlansoprazole","slug":"dexlansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":null},{"indication":"Heartburn","otherDrugs":[{"name":"almasilate","slug":"almasilate","company":""},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"magnesium carbonate","slug":"magnesium-carbonate","company":"United Guardian"}],"globalPrevalence":320000000},{"indication":"Indigestion","otherDrugs":[{"name":"almasilate","slug":"almasilate","company":""},{"name":"bismuth subsalicylate","slug":"bismuth-subsalicylate","company":"Prometheus Labs"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"},{"name":"cimetidine","slug":"cimetidine","company":""}],"globalPrevalence":null},{"indication":"Peptic ulcer","otherDrugs":[{"name":"almasilate","slug":"almasilate","company":""},{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"dexlansoprazole","slug":"dexlansoprazole","company":"Takeda Pharms Usa"},{"name":"esomeprazole","slug":"esomeprazole","company":"Astrazeneca Pharms"}],"globalPrevalence":64000000}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"algeldrate","explanation":"","oneSentence":"","technicalDetail":"Gaviscon (ALGELDRATE) forms a raft-like structure on the surface of the stomach contents, which helps to neutralize stomach acid and prevent it from coming into contact with the stomach lining, thereby reducing symptoms of gastroesophageal reflux disease and other gastrointestinal conditions."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Antacid","title":"Antacid","extract":"An antacid is a substance which neutralizes stomach acidity and is used to relieve heartburn, indigestion, or an upset stomach. Some antacids have been used in the treatment of constipation and diarrhea. Marketed antacids contain salts of aluminium, calcium, magnesium, or sodium. Some preparations contain a combination of two salts, such as magnesium carbonate and aluminium hydroxide."},"commercial":{"launchDate":"1983","_launchSource":"DrugCentral (FDA 1983-12-09, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4250","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALGELDRATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALGELDRATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Antacid","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:36:51.280726","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:42:23.023221+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"aluminium phosphate","drugSlug":"aluminium-phosphate","fdaApproval":"","relationship":"same-class"}],"genericName":"algeldrate","indications":{"approved":[{"name":"Duodenal ulcer disease","source":"DrugCentral","snomedId":51868009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Gastric Hypersecretory Conditions","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Gastric ulcer","source":"DrugCentral","snomedId":397825006,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Gastroesophageal reflux disease","source":"DrugCentral","snomedId":235595009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Heartburn","source":"DrugCentral","snomedId":16331000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","globalPrevalence":320000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"BMC Pregnancy Childbirth, 2025 (PMID:41366751)"},{"name":"Indigestion","source":"DrugCentral","snomedId":162031009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Peptic ulcer","source":"DrugCentral","snomedId":13200003,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Aliment Pharmacol Ther, 2009 (PMID:19220208)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"aluminium-phosphate","brandName":"aluminium phosphate","genericName":"aluminium phosphate","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06745921","phase":"PHASE1","title":"Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-24","conditions":["West Nile Viral Infection"],"enrollment":30,"completionDate":"2027-11-01"},{"nctId":"NCT07221162","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-05","conditions":["COVID-19"],"enrollment":140,"completionDate":"2026-11-24"},{"nctId":"NCT07003984","phase":"PHASE3","title":"A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.","status":"RECRUITING","sponsor":"Bavarian Nordic","startDate":"2025-06-05","conditions":["Chikungunya Virus"],"enrollment":720,"completionDate":"2028-12"},{"nctId":"NCT07310927","phase":"PHASE2,PHASE3","title":"Alginate vs Sucralfate for GERD Symptomatic Relief","status":"RECRUITING","sponsor":"CMH Lahore Medical College and Institute of Dentistry","startDate":"2025-04-01","conditions":["GERD"],"enrollment":140,"completionDate":"2026-04"},{"nctId":"NCT06719219","phase":"PHASE1","title":"A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-01-07","conditions":["Staphylococcus (S.) Aureus Infection"],"enrollment":129,"completionDate":"2026-03-04"},{"nctId":"NCT07467707","phase":"PHASE3","title":"An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","status":"NOT_YET_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2026-05","conditions":["Chikungunya Virus"],"enrollment":6144,"completionDate":"2030-05"},{"nctId":"NCT07216430","phase":"PHASE2","title":"Safety and Efficacy of wSp Vaccine in Young Children","status":"RECRUITING","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-09-29","conditions":["Acute Otitis Media (AOM)"],"enrollment":320,"completionDate":"2029-06"},{"nctId":"NCT03172975","phase":"PHASE2","title":"Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2018-03-01","conditions":["Hookworm Infections"],"enrollment":39,"completionDate":"2025-01-30"},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":["Rotavirus Infections"],"enrollment":50,"completionDate":"2026-02-04"},{"nctId":"NCT06680479","phase":"PHASE1","title":"Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-01","conditions":["HIV-1"],"enrollment":30,"completionDate":"2028-04-14"},{"nctId":"NCT04915768","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-23","conditions":["HIV Infections"],"enrollment":51,"completionDate":"2025-07-15"},{"nctId":"NCT05018585","phase":"PHASE3","title":"A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2022-05-19","conditions":["Type 1 Diabetes Mellitus"],"enrollment":330,"completionDate":"2027-12"},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":["COVID -19","SARS CoV 2 Infection"],"enrollment":1919,"completionDate":"2024-06-27"},{"nctId":"NCT06592586","phase":"PHASE2,PHASE3","title":"A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women","status":"RECRUITING","sponsor":"Minervax ApS","startDate":"2025-03-07","conditions":["Streptococcus Agalactiae Infection","Neonatal Sepsis","Pneumonia","Meningitis","Neonatal Infection","Gram-Positive Bacterial Infections","Bacterial Infections","Bacterial Infections and Mycoses","Infections"],"enrollment":338,"completionDate":"2029-06-30"},{"nctId":"NCT04985760","phase":"PHASE1","title":"Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy","status":"COMPLETED","sponsor":"Madhu Chhanda Choudhary","startDate":"2021-09-30","conditions":["HIV Infections"],"enrollment":32,"completionDate":"2026-01-16"},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":["Hepatitis B"],"enrollment":122,"completionDate":"2024-11-29"},{"nctId":"NCT06613789","phase":"PHASE1","title":"Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected","status":"NOT_YET_RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2026-07-13","conditions":["HIV Infections"],"enrollment":22,"completionDate":"2027-06-03"},{"nctId":"NCT02014727","phase":"PHASE1","title":"Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-01","conditions":["Malaria, Falciparum"],"enrollment":66,"completionDate":"2015-07"},{"nctId":"NCT02658253","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2016-01","conditions":["Malaria"],"enrollment":68,"completionDate":"2019-02-21"},{"nctId":"NCT03910972","phase":"PHASE1,PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":["Schistosomiasis","Schistosoma Mansoni"],"enrollment":290,"completionDate":"2024-11-13"},{"nctId":"NCT07059182","phase":"PHASE1","title":"Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-06-11","conditions":["PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE","Prevention of Pneumococcal-induced Acute Otitis Media"],"enrollment":30,"completionDate":"2025-08-29"},{"nctId":"NCT03934541","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-08-26","conditions":["HIV Infections"],"enrollment":24,"completionDate":"2021-05-26"},{"nctId":"NCT06796686","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-17","conditions":["HIV"],"enrollment":42,"completionDate":"2027-01-15"},{"nctId":"NCT06145178","phase":"PHASE1","title":"A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants","status":"COMPLETED","sponsor":"SpyBiotech Limited","startDate":"2023-11-22","conditions":["Cytomegalovirus Infections"],"enrollment":120,"completionDate":"2025-07-09"},{"nctId":"NCT03038802","phase":"PHASE1,PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":["Chronic Hepatitis b"],"enrollment":40,"completionDate":"2027-06-30"},{"nctId":"NCT05901636","phase":"PHASE1,PHASE2","title":"A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2023-05-17","conditions":["Influenza Prevention"],"enrollment":170,"completionDate":"2024-08-19"},{"nctId":"NCT05782179","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants","status":"COMPLETED","sponsor":"Minervax ApS","startDate":"2023-03-01","conditions":["Group B Streptococcal Infections"],"enrollment":90,"completionDate":"2024-05-23"},{"nctId":"NCT04177355","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-13","conditions":["HIV Infections"],"enrollment":127,"completionDate":"2024-11-04"},{"nctId":"NCT07085702","phase":"PHASE1","title":"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-31","conditions":["Streptococcal Infections"],"enrollment":108,"completionDate":"2026-11-30"},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":["Cervical Intraepithelial Neoplasia","Cervical Cancer","Persistent Infection"],"enrollment":2188,"completionDate":"2026-12-31"},{"nctId":"NCT04658667","phase":"PHASE1","title":"HIV Vaccine in HIV-uninfected Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-02-03","conditions":["HIV"],"enrollment":81,"completionDate":"2024-07-01"},{"nctId":"NCT02952833","phase":"PHASE1","title":"ZIKA Vaccine in Naive Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-14","conditions":["Zika Virus Infection"],"enrollment":91,"completionDate":"2018-12-05"},{"nctId":"NCT07078357","phase":"PHASE1,PHASE2","title":"Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-10-01","conditions":["Rheumatic Heart Disease","Rheumatic Heart Disease in Children","Vaccine Adverse Reaction","Rheumatic Diseases","Vaccine Acceptance","Vaccine"],"enrollment":60,"completionDate":"2028-12-01"},{"nctId":"NCT04193189","phase":"PHASE3","title":"B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-14","conditions":["HIV Infection","Hepatitis B"],"enrollment":638,"completionDate":"2024-08-13"},{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":["Hookworm Infection","Hookworm Disease"],"enrollment":24,"completionDate":"2016-10"},{"nctId":"NCT04566484","phase":"PHASE2,PHASE3","title":"Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia","status":"TERMINATED","sponsor":"International Vaccine Institute","startDate":"2021-08-01","conditions":["Chikungunya"],"enrollment":3210,"completionDate":"2025-05-31"},{"nctId":"NCT06541093","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.","status":"COMPLETED","sponsor":"Uvax Bio LLC","startDate":"2024-01-30","conditions":["AIDS/HIV - RelatedDisease Associated With AIDS","Vaccine-Preventable Diseases","HIV Infections"],"enrollment":34,"completionDate":"2025-03-21"},{"nctId":"NCT03589768","phase":"PHASE2","title":"Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-01-24","conditions":["Clostridium Difficile Immunisation","Diphtheria","Diphtheria Immunisation","Pertussis","Tetanus","Tetanus Immunisation"],"enrollment":399,"completionDate":"2020-07-01"},{"nctId":"NCT04658914","phase":"PHASE2","title":"Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2021-04-15","conditions":["Diarrhea","Diarrhea Rotavirus"],"enrollment":720,"completionDate":"2023-01-30"},{"nctId":"NCT04898283","phase":"PHASE3","title":"Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2021-05-31","conditions":["Rhinitis, Allergic","Rhinoconjunctivitis","Asthma, Allergic"],"enrollment":180,"completionDate":"2026-10"},{"nctId":"NCT04435990","phase":"PHASE3","title":"Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2020-10-06","conditions":["Rhinitis, Allergic","Rhinoconjunctivitis","Asthma, Allergic"],"enrollment":150,"completionDate":"2026-12"},{"nctId":"NCT04891237","phase":"PHASE3","title":"Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2021-06-14","conditions":["Rhinitis, Allergic","Rhinoconjunctivitis","Asthma, Allergic"],"enrollment":180,"completionDate":"2027-01"},{"nctId":"NCT06241183","phase":"PHASE4","title":"Famotidine and Antacids for Treatment of Dyspepsia","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2023-11-09","conditions":["Dyspepsia","GERD","Acid Reflux"],"enrollment":80,"completionDate":"2025-12"},{"nctId":"NCT06465420","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventVacc Biologicals Inc.","startDate":"2024-05-29","conditions":["Haemophilus Influenzae Meningitis","Invasive Haemophilus Influenzae Disease"],"enrollment":30,"completionDate":"2025-09-15"},{"nctId":"NCT06007183","phase":"PHASE3","title":"Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2023-08-30","conditions":["Chikungunya Virus Infection"],"enrollment":800,"completionDate":"2028-08"},{"nctId":"NCT05013983","phase":"PHASE1,PHASE2","title":"Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents","status":"WITHDRAWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-07","conditions":["COVID-19"],"enrollment":0,"completionDate":"2025-12"},{"nctId":"NCT04904471","phase":"PHASE3","title":"A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2021-06-15","conditions":["COVID-19"],"enrollment":39663,"completionDate":"2023-11-01"},{"nctId":"NCT06267872","phase":"PHASE1","title":"A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-10-07","conditions":["HIV"],"enrollment":0,"completionDate":"2026-09-12"},{"nctId":"NCT04826094","phase":"PHASE1","title":"A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-15","conditions":["HIV Infections"],"enrollment":143,"completionDate":"2024-02-13"},{"nctId":"NCT06819033","phase":"PHASE4","title":"Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-03-10","conditions":["Aphthous Ulcer"],"enrollment":30,"completionDate":"2026-02-28"},{"nctId":"NCT04862416","phase":"PHASE1","title":"Safety and Efficacy of R0.6C Vaccine","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-05-17","conditions":["Malaria","Malaria,Falciparum"],"enrollment":32,"completionDate":"2022-06-29"},{"nctId":"NCT05303584","phase":"PHASE4","title":"Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-04-23","conditions":["COVID-19"],"enrollment":362,"completionDate":"2023-05-31"},{"nctId":"NCT03461276","phase":"PHASE2","title":"Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD","status":"COMPLETED","sponsor":"Araclon Biotech S.L.","startDate":"2017-12-13","conditions":["Mild Cognitive Impairment","Alzheimer Disease"],"enrollment":134,"completionDate":"2023-03-23"},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":["Hepatitis B Vaccine"],"enrollment":40,"completionDate":"2026-11-05"},{"nctId":"NCT06524947","phase":"PHASE3","title":"Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2024-07-27","conditions":["Acute Gastroenteropathy Due to Norovirus"],"enrollment":6600,"completionDate":"2027-03-28"},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":["HIV Infections"],"enrollment":1512,"completionDate":"2024-12-31"},{"nctId":"NCT02839161","phase":"PHASE1","title":"Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2017-01","conditions":["Hookworm Disease","Hookworm Infection"],"enrollment":60,"completionDate":"2019-03-28"},{"nctId":"NCT01385189","phase":"PHASE1","title":"Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-05","conditions":["Hookworm Infection","Hookworm Disease"],"enrollment":40,"completionDate":"2015-06"},{"nctId":"NCT05349617","phase":"PHASE3","title":"Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2022-05-12","conditions":["Chikungunya Virus"],"enrollment":413,"completionDate":"2023-08-08"},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":["Malaria"],"enrollment":301,"completionDate":"2020-07-15"},{"nctId":"NCT05621655","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-01-08","conditions":["Rotavirus Infections","Rotavirus Gastroenteritis"],"enrollment":1512,"completionDate":"2024-12"},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":["Gonorrhoea"],"enrollment":52,"completionDate":"2023-10-02"},{"nctId":"NCT06332339","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-03-15","conditions":["HIV"],"enrollment":45,"completionDate":"2026-11-11"},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":["H7N9 Influenza"],"enrollment":560,"completionDate":"2019-11-15"},{"nctId":"NCT03369808","phase":"PHASE1,PHASE2","title":"A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2017-12-29","conditions":["H7N9 Influenza"],"enrollment":360,"completionDate":"2019-11-15"},{"nctId":"NCT04563533","phase":"PHASE1,PHASE2","title":"Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-08-05","conditions":["Acute Gastroenteritis"],"enrollment":580,"completionDate":"2024-09-29"},{"nctId":"NCT06503978","phase":"PHASE2","title":"Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gut-Brain-Axis Therapeutics Inc.","startDate":"2024-08-20","conditions":["Autism Spectrum Disorder","Gastro-Intestinal Disorder","Constipation","Diarrhea"],"enrollment":60,"completionDate":"2026-08-17"},{"nctId":"NCT03284710","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-19","conditions":["HIV Infections"],"enrollment":132,"completionDate":"2019-12-12"},{"nctId":"NCT05072080","phase":"PHASE3","title":"A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2021-09-29","conditions":["Chikungunya Virus"],"enrollment":3258,"completionDate":"2023-04-03"},{"nctId":"NCT06058416","phase":"PHASE4","title":"Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-10-24","conditions":["Hepatitis A"],"enrollment":1092,"completionDate":"2029-12-31"},{"nctId":"NCT06494475","phase":"PHASE2,PHASE3","title":"GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"Minervax ApS","startDate":"2024-12-17","conditions":["Streptococcus Agalactiae Infection"],"enrollment":564,"completionDate":"2025-06-21"},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":["COVID-19"],"enrollment":1750,"completionDate":"2023-03-09"},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":["COVID-19"],"enrollment":10214,"completionDate":"2022-07-27"},{"nctId":"NCT04602975","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a","status":"COMPLETED","sponsor":"Institut Pasteur","startDate":"2020-10-06","conditions":["Healthy"],"enrollment":248,"completionDate":"2023-11-15"},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":["Zika Virus Infection"],"enrollment":75,"completionDate":"2018-10-30"},{"nctId":"NCT06350058","phase":"PHASE1","title":"Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-08-03","conditions":["Healthy Volunteers"],"enrollment":375,"completionDate":"2024-10-31"},{"nctId":"NCT02690181","phase":"PHASE2","title":"Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-29","conditions":["Bacterial Infection Due to Streptococcus, Group B","Streptococcus Agalactiae"],"enrollment":80,"completionDate":"2016-11-02"},{"nctId":"NCT05409300","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-25","conditions":["COVID-19","Vaccine Adverse Reaction","Sars-CoV-2 Infection","Healthy Volunteer"],"enrollment":200,"completionDate":"2025-02"},{"nctId":"NCT00605085","phase":"PHASE3","title":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":["Japanese Encephalitis"],"enrollment":2675,"completionDate":"2006-11"},{"nctId":"NCT06321796","phase":"PHASE2","title":"Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders","status":"RECRUITING","sponsor":"Gut-Brain-Axis Therapeutics Inc.","startDate":"2024-02-27","conditions":["Pitt Hopkins Syndrome"],"enrollment":20,"completionDate":"2025-05"},{"nctId":"NCT02771730","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults","status":"TERMINATED","sponsor":"Emergent BioSolutions","startDate":"2015-03","conditions":["Healthy Volunteer","HIV Vaccine"],"enrollment":20,"completionDate":"2017-02"},{"nctId":"NCT05469802","phase":"PHASE2","title":"A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2024-01-02","conditions":["Healthy Volunteers"],"enrollment":0,"completionDate":"2024-07-05"},{"nctId":"NCT05417269","phase":"PHASE1,PHASE2","title":"IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imcyse SA","startDate":"2022-04-12","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":150,"completionDate":"2025-12-31"},{"nctId":"NCT06282692","phase":"PHASE3","title":"INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-06-19","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":400,"completionDate":"2024-07-19"},{"nctId":"NCT06272253","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-09-19","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":250,"completionDate":"2024-07-19"},{"nctId":"NCT06259578","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2024-01-29","conditions":["COVID-19 Pandemic","COVID-19 Vaccines","COVID-19 Virus Disease"],"enrollment":400,"completionDate":"2024-12-29"},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":["COVID-19","Vaccines"],"enrollment":551,"completionDate":"2023-10-26"},{"nctId":"NCT05131373","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-28","conditions":["Acne Vulgaris","Acne"],"enrollment":38,"completionDate":"2023-11-27"},{"nctId":"NCT04874714","phase":"PHASE3","title":"Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis","status":"TERMINATED","sponsor":"Inmunotek S.L.","startDate":"2021-04-30","conditions":["Allergic Rhinoconjunctivitis","Perennial Allergic Rhinitis","House Dust Mite Allergy","Pollen Allergy"],"enrollment":18,"completionDate":"2023-10-09"},{"nctId":"NCT04912076","phase":"PHASE1","title":"S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2018-09-17","conditions":["Birch Pollen Allergy","Allergic Rhinoconjunctivitis"],"enrollment":47,"completionDate":"2019-03-22"},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":["COVID-19 Vaccination"],"enrollment":400,"completionDate":"2025-12-31"},{"nctId":"NCT05351879","phase":"PHASE1,PHASE2","title":"Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes","status":"COMPLETED","sponsor":"Linkoeping University","startDate":"2022-05-09","conditions":["Diabetes Mellitus, Type 1"],"enrollment":6,"completionDate":"2023-08-29"},{"nctId":"NCT05112913","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-27","conditions":["COVID-19"],"enrollment":2520,"completionDate":"2023-12-25"},{"nctId":"NCT05329038","phase":"PHASE4","title":"Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-04-19","conditions":["COVID-19"],"enrollment":180,"completionDate":"2024-02-20"},{"nctId":"NCT05198596","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-30","conditions":["COVID-19 Vaccine"],"enrollment":250,"completionDate":"2023-03-30"},{"nctId":"NCT05426343","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-09","conditions":["COVID-19 Vaccine"],"enrollment":200,"completionDate":"2023-01-07"},{"nctId":"NCT05137418","phase":"PHASE3","title":"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-27","conditions":["COVID-19"],"enrollment":1000,"completionDate":"2023-01-27"},{"nctId":"NCT04992260","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-09-10","conditions":["COVID-19"],"enrollment":11349,"completionDate":"2023-05-31"},{"nctId":"NCT04993365","phase":"PHASE4","title":"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-05","conditions":["COVID-19"],"enrollment":520,"completionDate":"2022-07-14"},{"nctId":"NCT05198336","phase":"PHASE4","title":"Immunogenicity of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-01-08","conditions":["COVID-19"],"enrollment":395,"completionDate":"2022-12-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Cream, Gel, Granule, Liquid","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"ISA KNOX AGELESS SERUM MAKEUP BASE 10"},{"form":"CREAM","route":"TOPICAL","productName":"ISAKNOX AGELESS SERUM BLEMISH BALM"},{"form":"GEL","route":"ORAL","productName":"Aluminum Hydroxide"},{"form":"GRANULE","route":"ORAL","productName":"INON"},{"form":"LIQUID","route":"ORAL","productName":"Antacid"},{"form":"LIQUID","route":"ORAL","productName":"Antacid Antigas"},{"form":"LIQUID","route":"ORAL","productName":"Antacid antigasMaximum Strength"},{"form":"LIQUID","route":"ORAL","productName":"Antacid antigasRegular Strength"},{"form":"LIQUID","route":"ORAL","productName":"Maximum Strength Antacid Cherry liquid"},{"form":"LIQUID","route":"ORAL","productName":"Maximum Strength Antacid Mint"},{"form":"LIQUID","route":"ORAL","productName":"Quality Choice Maximum Strength Antacid"},{"form":"LIQUID","route":"ORAL","productName":"Regular Strength Antacid Antigas"},{"form":"LIQUID","route":"ORAL","productName":"Regular Strength Antacid Mint"},{"form":"LIQUID","route":"ORAL","productName":"maximum strength antacid cherry"},{"form":"LIQUID","route":"ORAL","productName":"ACID GONE ANTACID"}]},"crossReferences":{"NUI":"N0000146920","MMSL":"4159","NDDF":"001123","UNII":"03J11K103C","VUID":"4018607","CHEBI":"CHEBI:33130","VANDF":"4017984","INN_ID":"1945","RXNORM":"612","UMLSCUI":"C0002371","chemblId":"CHEMBL3833310","ChEMBL_ID":"CHEMBL3833310","KEGG_DRUG":"D02807","DRUGBANK_ID":"DB06723","PUBCHEM_CID":"6328660","SNOMEDCT_US":"273944007","SECONDARY_CAS_RN":"1330-44-5","MESH_DESCRIPTOR_UI":"D000536"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1983-","companyName":"Sanofi","relationship":"Original Developer"}],"publicationCount":2,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"A02AB01","allCodes":["A02AB01","A02AB02"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"1996 Jun","pmid":"8767354","title":"Comparison of the effects of ranitidine effervescent tablets and magnesium hydroxide-aluminium oxide on intragastric acidity. A single-centre, randomised, open cross-over study.","journal":"Arzneimittel-Forschung"},{"date":"1986-1987","pmid":"3573126","title":"Intestinal absorption of aluminium from antacids: a comparison between hydrotalcite and algeldrate.","journal":"Journal of toxicology. Clinical toxicology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"1983","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1983-12-09T00:00:00.000Z","mah":"CHATTEM SANOFI","brand_name_local":"GAVISCON","application_number":"NDA018685"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:42:23.023221+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}